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ABSTRACT. A small library of integrin ligand - Paclitaxel conjugates 10-13 was synthesized 
with the aim of using the tumor-homing cyclo[DKP-RGD] peptidomimetics for site-directed 
delivery of the cytotoxic drug. All the Paclitaxel-RGD constructs 10-13 inhibited biotinylated 
vitronectin binding to the purified αVβ3 integrin receptor at low nanomolar concentration and 
showed in vitro cytotoxic activity against a panel of human tumor cell lines similar to that of 
Paclitaxel. Among the cell lines, the cisplatin-resistant IGROV-1/Pt1 cells expressed high levels 
of integrin αVβ3, making them attractive to be tested in in vivo models. Cyclo[DKP-f3-RGD]-
PTX 11 displayed sufficient stability in physiological solution and in both human and murine 
plasma to be a good candidate for in vivo testing. In tumor-targeting experiments against the 
IGROV-1/Pt1 human ovarian carcinoma xenotransplanted in nude mice, compound 11 exhibited 
a superior activity than Paclitaxel, despite the lower (ca. half) molar dosage used. 
 
INTRODUCTION 
Chemotherapy has been one of the main approaches for the treatment of cancer for more than 
half a century and is based on the administration of drugs which often interfere with fundamental 
cellular functions (e.g., DNA replication, cell division). The antitumor efficacy of anticancer 
drugs is thus limited by their nonspecific toxicity to normal cells, especially to rapidly growing 
cells such as blood, bone marrow and mucous membrane cells, resulting in a low therapeutic 
index and serious side-effects. The efficacy of chemotherapy is further limited by the occurrence 
or development of drug resistance: tumor cells can be regarded as a rapidly changing target 
because of their genetic instability, heterogeneity, and high rate of mutation, leading to selection 
and overgrowth of a drug-resistant tumor cell population.1 In principle, the efficiency of the 
treatment can be improved by increasing the doses, but this approach commonly results in severe 
toxicity. Therefore, selective tumor targeting of chemotherapeutic agents represents a major goal, 
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and various drug delivery systems have been recently developed,2 including the use of 
liposomes, microspheres, micelles, polymers, protein- or antibody-drug conjugates, and pro-
drugs.3 Considerable efforts are currently being made in this domain to such an extent that 
leaders of major pharmaceutical companies foresee that >60% of all existing drugs will be 
targeted in less than two decades.4 In this field, an attractive avenue for selective tumor targeting 
are hybrid molecules designed to bind to specific over-expressed receptors on cancer cells.5 
Clearly, the success of this approach is heavily dependent on the rational selection of appropriate 
biological objectives. 
Integrins are ideal pharmacological targets based on their key role in angiogenesis and tumor 
development and on their easy accessibility as cell surface receptors interacting with 
extracellular ligands.6 They are bidirectional glycoprotein heterodimeric receptors which connect 
cells to the scaffolding proteins of the extracellular matrix, occurring in at least 24 pairs of 18 α 
and 8 β subunits and containing large extracellular domains and short cytoplasmic domains.7 
Integrins are also involved in tissue integrity and cell trafficking, growth, differentiation, 
proliferation and migration.8  As a consequence of their role in so many fundamental processes, 
integrin malfunction is connected to a large variety of diseases such as thrombosis, osteoporosis, 
inflammation, and cancer.9 The tripeptide sequence arginine-glycine-aspartate (RGD) has been 
identified as the common motif used by several endogenous ligands to recognize and bind a 
group of integrins, including αVβ3, αVβ5, α5β1, which are crucial in angiogenesis, tumor 
progression and metastasis, and αIIbβ3, which is involved in platelet aggregation.
10 
A potent αVβ3 integrin ligand, cyclo[Arg-Gly-Asp-D-Phe-N(Me)-Val] (Cilengitide) developed 
by Kessler and co-workers (Figure 1),11,12 is currently in phase III clinical trials as an 
angiogenesis inhibitor for patients with glioblastoma multiforme.13 The high activity and 
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selectivity of this derivative has been attributed to an extended conformation of the RGD motif 
displaying a distance of about 9 Å between the Cβ atoms of Asp and Arg.
12,14 These observations 
prompted many other research groups to investigate the use of conformationally constrained 
cyclic RGD peptidomimetics as active and selective integrin antagonists. A selection of these 
ligands, encompassing a wide variety of rigid scaffolds and featuring 13-, 14-, 15- and 16-
membered rings, is shown in Figure 1.15 
 
Figure 1. Potent αVβ3 integrin ligands 
 
 
We have recently contributed to this field with a new class of cyclic RGD-peptidomimetics, 
containing bifunctional diketopiperazine (DKP) scaffolds and featuring 17-membered rings 
(Figure 2).16 The cis-derivative cyclo[DKP-1-RGD] (1) inhibited biotinylated vitronectin binding 
to the purified αVβ3 receptor at a micromolar concentration (3.9 ± 0.4 µM), while trans-
derivatives 2-7 ranged from submicro- to subnanomolar concentrations (220 - 0.2 nM). 
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Figure 2. Library of cyclo[DKP-RGD] integrin ligands 
 
a
N-dibenzyl cyclo[DKP-7-RGD] was isolated as two different separable conformers 
(diastereomers, 7a and 7b) due to hindered rotation of one ring around the other, i.e., the DKP N-
benzyl group cannot pass inside the macrolactam ring, see ref. 16b. 
 
It is now emerging that antiangiogenic therapy alone is not sufficient to fight and eradicate 
tumors: recent preclinical findings of a paradoxical pro-angiogenic activity of RGD-mimetic 
agents (like Cilengitide) at low concentrations have stimulated the debate on the use of 
antiangiogenetics as single drugs.17 Since αV integrins, which can be internalized by cells, are 
involved in tumor angiogenesis and are overexpressed on the surface of cancer cells, integrin 
ligands can be usefully employed as tumor-homing peptidomimetics for site-directed delivery of 
cytotoxic drugs.18 During the past fifteen years, a number of RGD-cytotoxic drug conjugates 
have been developed. In these approaches, a few cyclic RGD integrin ligands (e.g., RGD4C,19 
cyclo[(NMe)VRGDf-NH],20 cyclo[RGDfK],21,22 cyclo[CRGDC],22 cyclo[RGDf-Aad],23a 
cyclo[RGDf-Amp]23a) were conjugated to a cytotoxic drug (e.g., doxorubicin,19,21 doxsaliform,20 
camptothecin,23a,b cisplatin22) through different linkers, such as amides,19,22,23a oximes,20,23a 
maleimides,21 carbamates,23b and idrazones.23a Notably, Chen and co-workers prepared the RGD 
ligand - Paclitaxel conjugate 8 (Figure 3), which was covalently assembled by joining the 
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microtubule-stabilizing anticancer agent to the dimeric RGD peptide E[cyclo(RGDyK)]2 via a 
cleavable succinyl ester linker, and evaluated its antitumor activity on the metastatic breast 
cancer cell line MDA-MB-435.24 In mice, conjugate 8 showed a moderately improved antitumor 
effect over Paclitaxel, but no tumor regression could be observed. The stability of the succinyl 
linker was not assessed and a premature release of Paclitaxel can be suspected.  
 
Figure 3. Dimeric RGD ligand - Paclitaxel conjugates 
 
 
 
A very similar conjugate (i.e., compound 9 reported in Figure 3) was extensively evaluated in 
a recent study by Ryppa and co-workers on an ovarian carcinoma xenograft model (OVCAR-
3).25 Although the construct provided promising results in vitro, unfortunately it did not show 
any antitumor effect in vivo. The stability of conjugate 9 in a glucose phosphate buffer solution 
at pH=7 was studied over 24 h, yielding a half-life of only ~2 h at 37 °C. Half-life in the 
bloodstream is expected to be much shorter, and the inefficacy of this conjugate was attributed to 
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hydrolysis of the ester bond at the 2’ position of Paclitaxel, which causes premature release of 
the cytotoxic agent and loss of the tumor-homing effect. 
Herein, we present a full account of our investigations reporting: (i) the synthesis of new 
cyclo[DKP-RGD] integrin ligands, bearing a free amine group suitable for conjugation to a 
cytotoxic drug; (ii) the conjugation of these ligands to Paclitaxel via a succinyl linker to give 
cyclo[DKP-RGD] - Paclitaxel conjugates 10-13 (Figure 4); (iii) the stability of a cyclo[DKP-
RGD] - Paclitaxel construct in a physiological solution and in both human and murine plasma, 
which turned out to be far better than the case reported above;25 (iv) the ability of the 
cyclo[DKP-RGD] - Paclitaxel conjugates to compete with biotinylated vitronectin for binding to 
the purified αVβ3 and αVβ5 receptors; (v) in vitro cytotoxic activity of the cyclo[DKP-RGD] - 
Paclitaxel conjugates in a panel of human cancer cell lines; (vi) in vivo tumor-targeting efficacy 
against the IGROV-1/Pt1 human ovarian carcinoma xenotransplanted in nude mice; (vii) the 
effects of tumor treatment, analyzed using immunohistochemistry. 
 
 
 
 
 
 
 
 
 
 
Page 7 of 67
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 8
Figure 4. Structure of cyclo[DKP-RGD] - Paclitaxel conjugates 10-13 
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RESULTS AND DISCUSSION 
Synthesis. In order to prepare cyclic RGD-peptidomimetics covalently linked to Paclitaxel 
(compounds 10-13, Figure 4), four functionalized (f) trans diketopiperazines (i.e., DKP-f2, DKP-
f3, DKP-f4, DKP-f6) were synthesized, varying the position of the p-aminomethylbenzyl N-
substituent (N-1 or N-4) and the absolute stereochemistry at C-3 and C-6 (Schemes 1-3). These 
DKPs were used for the synthesis of cyclo[DKP-RGD] integrin ligands (Scheme 4), which were 
conjugated to 2’-succinyl Paclitaxel (Scheme 5). 
For the preparation of the functionalized trans diketopiperazines DKP-f2, DKP-f3, DKP-f4, 
and DKP-f6, we selected a linker bearing both an aldehyde (for successive reductive alkylation) 
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and an amino group (for the final conjugation to Paclitaxel). Thus, linker 14 was synthesized in 
three steps from 4-aminomethyl benzoic acid via LiAlH4 reduction, primary amine protection as 
4-methoxy-2,3,6-trimethylbenzenesulphonamide (Mtr) and benzylic alcohol oxidation using 
activated MnO2 (Scheme 1). The Mtr protecting group was chosen because of its stability and 
orthogonality with the methyl, benzyl, allyl, tBu, Boc, and Cbz protecting groups. 
 
Scheme 1. Synthesis of aldehyde 14a 
 
aReagents and conditions: (a) LiAlH4, THF, 8 h, reflux, 70%; (b) Mtr-Cl, i-Pr2NEt, THF, 6 h, 
room temp., 85%; (c) MnO2, THF, overnight, room temp., quant.. 
 
Trans scaffolds DKP-f2, DKP-f3 (Scheme 2) and DKP-f4, DKP-f6 (Scheme 3) were 
synthesized starting from commercially available (R)- or (S)-aspartic acid and (R)- or (S)-serine. 
Two different synthetic strategies were developed depending on the nitrogen substitution. In 
particular, the synthesis of DKP-f2 and DKP-f3 (bearing the linker on DKP nitrogen N-4, former 
serine nitrogen) was realized making use of a serine ligation strategy,26 as described in Scheme 
2. (R)- and (S)-Aspartic acid were initially protected as allyl ester on the side chain and as N-Boc 
to give the enantiomeric derivatives (S)-15 and (R)-16. (R)- and (S)-Serine were protected as 
methyl ester and reductively alkylated with aldehyde 14 and sodium triacetoxyborohydride to 
afford the enantiomeric compounds (R)-17 and (S)-18. Direct coupling (HATU, iPr2NEt) of 
protected aspartic acid (S)-15 with functionalized serine (R)-17, or of the enantiomers (R)-16 
with (S)-18, led to the isopeptides (S,R)-19 and (R,S)-20 in high yield (86%), rather than forming 
the expected dipeptides. The O,N-acyl migration26 was then triggered by cleavage of the Boc 
protecting group and treatment with a base (iPr2NEt) in a protic solvent (iPrOH), which also 
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promoted the simultaneous cyclization to the trans diketopiperazines 21 and 22 (93% overall 
yield). The hydroxyl group of 21 and 22 was converted into azides 23 and 24 via a Mitsunobu 
reaction in good yield (86%), using HN3‧Tol in a toluene / dichloromethane solution. Finally, a 
one-pot Staudinger reduction - Boc protection, followed by allyl deprotection yielded the trans 
scaffolds DKP-f2 (27; 3R,6S) and DKP-f3 (28; 3S,6R) in 88% yield. This synthetic route 
involves a high overall yield (60%) and only a few chromatographic purifications, which allows 
easy preparation on a multi-gram scale. 
 
Scheme 2. Synthesis of DKP-f2 and DKP-f3a,b 
 
aReagents and conditions: (a) allyl alcohol, AcCl; (b) Boc2O, TEA, Dioxane, water, 95% over 
two steps; (c) MeOH, AcCl, quant.; (d) aldehyde 14, NaBH(OAc)3, THF, 3 h, room temp., 
quant.; (e) HATU, HOAT, iPr2NEt, DMF, 3 h, 0 °C to room temp., 86%; (f) TFA/DCM 1:2, 3 h, 
0 °C to room temp.; (g) iPr2NEt, iPrOH, 6 h, room temp., 93% over two steps; (h) HN3
.Tol, 
DIAD, Ph3P, DCM/Tol 1:2, 7 h, -20 °C, 86%; (i) Me3P, BOC-ON, THF, 6 h, -20 °C to room 
temp., 88%; (j) pyrrolidine, PPh3, [Pd(PPh3)4], DCM, 4 h, room temp., quant.. 
bYields reported 
are the average of six experiments, including different reaction batches with the two 
enantiomeric products. 
 
For the synthesis of trans scaffolds DKP-f4 and DKP-f6 (Scheme 3), (R)- and (S)-aspartic acid 
were protected as dimethyl ester and reductively alkylated with aldehyde 14 to obtain the 
enantiomeric derivatives (S)-29 and (R)-30. The hydroxyl group of (R)- or (S)-Boc-Ser-OMe was 
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first transformed into the corresponding azide under Mitsunobu conditions in 78% yield and then 
the methyl ester was saponified. The resulting enantiomeric acids (R)-31 and (S)-32, stable only 
for a few hours, were immediately self-condensed with DCC in DCM to give the symmetric 
anhydrides (R,R)-33 and (S,S)-34, which were isolated by filtering off the N,N′-dicyclohexylurea 
(DCU) and immediately reacted with the functionalized aspartic acid dimethylester (S)-29 or (R)-
30 to obtain the enantiomeric dipeptides (S,R)-35 and (R,S)-36 in moderate yield (40%). Yield 
optimization was pursued by extensively varying the reaction conditions (equivalents, solvents, 
temperature, time) but all the attempts were not successful, and markedly differed from the 
analogous reaction run on N-benzyl-aspartic acid dimethylester (i.e. 29 or 30 missing the Mtr-
NH-CH2- side chain) where the yield was uniformly higher (80%).
16b All other coupling reagents 
tested (HATU, PyBrOP, DPPA, etc.) were ineffective for this reaction; although no coupling 
product of the dehydroalanine derivative was ever detected, the beta-elimination possibly caused 
by excess iPr2NEt in the HATU, PyBrOP and DPPA tentative couplings might be an additional 
reason for this failure, combined with the poor reactivity of the sterically hindered secondary 
amine of the aspartic derivative.  
After Boc deprotection, the six-membered cyclization occurred spontaneously with 4 equiv of 
iPr2NEt in iPrOH, to give diketopiperazines (3R,6S)-37 and (3S,6R)-38 in 92% yield. Trans 
scaffolds DKP-f4 (41; 3R,6S) and DKP-f6 (42; 3S,6R) were finally obtained by catalytic 
hydrogenation of the azide, Boc protection of the primary amine and hydrolysis of the methyl 
ester (96% overall yield). 
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Scheme 3. Synthesis of DKP-f4 and DKP-f6a,b 
 
aReagents and conditions: (a) MeOH, AcCl, quant.; (b) aldehyde 14, NaBH3(CN), MeOH, 4 h, 
room temp., 66%; (c) Boc2O, TEA, dioxane-water, 95%; (d) HN3
.Tol, DIAD, Ph3P, THF, 7 h, -
20 °C, 78%; (e) LiOH, H2O/THF 1:1, 1 h, 0 °C, quant.; (f) DCC, DCM, 1 h, room temp., quant.; 
(g) DCM, overnight, room temp., 40%; (h) TFA, Et3SiH, DCM, 3 h, room temp., quant.; (i) 
iPr2NEt, iPrOH, 6 h, room temp., 92%; (j) H2, 10% Pd/C, THF, 4 h, room temp., quant.; (k) 
Boc2O, iPr2NEt, DCM, 6 h, room temp., 96%. 
bYields reported are the average of six 
experiments, including different reaction batches with the two enantiomeric products. 
 
Trans diketopiperazines DKP-f2, DKP-f3, DKP-f4 and DKP-f6 were used as scaffolds for the 
synthesis of functionalized cyclo[DKP-RGD] integrin ligands 63-66, following a solution-phase 
strategy (Scheme 4). Dipeptide Boc-Arg(Mtr)-Gly-OBn, prepared on a multigram scale 
following our reported procedure,16b was Boc-deprotected and coupled to the chosen 
diketopiperazine scaffold to give compounds 43-46 in good yields (83-85%). The Boc protecting 
group of compounds 43-46 was then removed and the resulting free amines 47-50 were coupled 
to Cbz-Asp(OtBu)-OH to obtain the linear Cbz-Asp(OtBu)-DKP-Arg(Mtr)-Gly-OBn 
peptidomimetics 51-54 in high yields (86-88%). After carboxybenzyl and benzyl groups 
simultaneous deprotection by catalytic hydrogenolysis to give 55-58 quantitatively, the synthesis 
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of protected cyclo(DKP-RGD) 59-62 was accomplished in good yield (60-81%) by 17-
membered macrolactamization in a highly diluted DMF solution (1.4 mM) utilizing HATU, 
HAOT, i-Pr2NEt (4:4:6 equiv). The final step was the non trivial removal of the side chain 
protecting groups.  
 
Scheme 4. Synthesis of functionalized cyclo[DKP-RGD] integrin ligands 63-66a 
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63 [(3R, 6S), R1= H, R2= X] = cyclo[DKP-f2-RGD]
64 [(3S, 6R), R1= H, R2= X] = cyclo[DKP-f3-RGD]
65 [(3R, 6S), R1= X, R2= H] = cyclo[DKP-f4-RGD]
66 [(3S, 6R), R1= X, R2= H] = cyclo[DKP-f6-RGD]
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X =
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a b c
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6
47-50
59-62
51-54
27 [(3R, 6S), R1= H, R2= CH2C6H4CH2NHMtr] = DKP-f2
28 [(3S, 6R), R1= H, R2= CH2C6H4CH2NHMtr] = DKP-f3
41 [(3R, 6S), R1= CH2C6H4CH2NHMtr, R
2= H] = DKP-f4
42 [(3S, 6R), R1= CH2C6H4CH2NHMtr, R
2= H] = DKP-f6 43-46
55-58
6
5
3
2
_
TFA
_
 
aReagents and conditions:  (a) HATU, HOAT, iPr2NEt, DMF, overnight, room temp., 83-85%; 
(b) TFA/DCM 1:2, 3 h, room temp., quant.; (c) Cbz-Asp(OtBu)-OH, HATU, HOAT, iPr2NEt, 
DMF, overnight, room temp., 86-88%; (d) H2, 10% Pd/C, THF/H2O 1:1, overnight, room temp., 
quant.; (e) HATU, HOAT, iPr2NEt, 1.4 mM in DMF, overnight, room temp., 60-81%; (f) 
TFA/TMSBr/thioanisol/EDT/phenol 70:14:10:5:1, 2 h, room temp., 70-85%. 
 
The OtBu and the Mtr on the arginine were easily deprotected while the Mtr on the benzylic 
amine was very stable. Several cleavage cocktails were screened and the more classic27 
[“Reagent K” (TFA/phenol/water/TIPS, 88/5/5/2),  “Reagent R” (TFA/thioanisole/EDT/anisole, 
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90/5/3/2) and “Reagent P+” (TFA/phenol/methanesulfonic acid, 95/2.5/2.5)] failed, giving the 
mono-protected compound as main product (the Mtr on the amine was still present), with a low 
yield (5-20%) of the desired totally deprotected product, even after 48 h. Finally, with the use of 
TFA/TMSBr/thioanisole/EDT/phenol (70/14/10/5/1) cleavage cocktail at room temperature for 2 
h, fully deprotected compounds 63-66 were obtained in 70-85% isolated yield.  
Thus, we were ready to conjugate Paclitaxel to our ligands: the 2’-hydroxyl function of 
Paclitaxel was derivatized with succinic anhydride, following a reported procedure.28 The 
resulting Paclitaxel hemisuccinate ester 6728 was activated using diisopropylcarbodiimide (DIC) 
and N-hydroxysulfosuccinimide sodium salt (sulfo-NHS), followed by coupling with 
cyclo[DKP-RGD] ligands 63-66 (Scheme 5).  
 
Scheme 5. Synthesis of cyclo[DKP-RGD] - PTX conjugates 10-13a 
 
aReagents and conditions: (a) succinic anhydride, py, DCM, overnight, 0 °C to room temp., 
94%; (b) N-hydroxysulfosuccinimide sodium salt, DIC, DMF, overnight, room temp.; (c) 
cyclo(DKP-RGD) 63, 64, 65 or 66, CH3CN, aq. phosphate buffer, pH = 7.3, 10 h at 0 °C then 8 h 
at room temp., 60-70%. 
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The conjugation yield was strongly pH-dependent: at pH < 7.0 the reaction did not proceed, 
whereas at pH > 7.5 the hydrolysis of the sulfo-NHS ester substantially competed with the 
primary amine reaction. The synthesis of conjugates 10-13 was finally achieved in good yield 
(60-70%) by adding a 0.1 M aqueous NaOH solution when required throughout the reaction, for 
maintaining the pH value at 7.3. 
 
Solubility and stability in a physiological solution. The solubility of conjugate cyclo[DKP-
f3-RGD]-PTX 11 was investigated in a physiological solution (0.9% NaCl in H2O)/Cremophor 
EL/ethanol (90:5:5 v/v) by quantitative HPLC. A 1.92 mM clear solution turned out to be 
oversaturated and slowly flocculated to reach a concentration of 1.28 mM in 2 days (Figure 5, 
left diagram). The precipitate was the conjugate 11 itself, with a purity > 99.5%. Compound 11 
(1.28 µmol) dissolved in 0.1 mL of Cremophor EL/ethanol (1:1 v/v) and diluted with 0.9 mL of 
physiological solution, was perfectly stable for one week, with a purity > 99.5%. The 1.28 mM 
solution did not undergo any precipitation or decomposition (Figure 5, right diagram).  
 
Figure 5. Solubility and stability of cyclo[DKP-f3-RGD]-PTX 11 in a physiological solutiona 
0 1 2 3 4 5 6 7
0
200
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1000
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1400
Conjugate 11 1.92 mM
Time (Days)
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re
a
0 1 2 3 4 5 6 7
0
200
400
600
800
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1200
1400
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Time (Days)
A
re
a
 
aQuantitative HPLC determination of solubility and stability of compound 11 in a 
physiological solution (0.9% NaCl in H2O)/Cremophor EL/ethanol (90:5:5 v/v). A 1.92 mM 
clear solution of 11 turned out to be oversaturated and slowly flocculated to reach a 
concentration of 1.28 mM in 2 days (left diagram). The 1.28 mM solution did not undergo any 
precipitation or decomposition over seven days (right diagram). 
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Plasma stability assays. Paclitaxel conjugate 11 (1.28 µmol) was dissolved in DMSO (128 
µL) and then diluted with pH 7.5 phosphate buffer (PBS) to give a 200 µM stock solution. 
Murine plasma was spiked with the stock solution to obtain a final 10 µM concentration and 
incubated at 37 °C. At time points varying from 1 min to 330 min, aliquots of 50 µL were taken 
and quenched with 200 µL of ice-cold acetonitrile (containing Verapamil as internal standard, 
see the Experimental Section for details). Samples were centrifuged at 3000 rpm for 20 min and 
the supernatant was analyzed by RP-HPLC UV-MS/MS. The data were fitted using a signal 
phase exponential decay and the calculated half-life was = 165 ± 2 min (Figure 6, left diagram). 
The same procedure was adopted for a pooled human plasma stability assay and in this case the 
calculated half-life was = 143 ± 3 min (Figure 6, right diagram). Free Paclitaxel accumulated 
during the assays as a result of hydrolysis of the succinyl ester bond at the PTX-2’ position. 
These results were very encouraging and showed that cyclo[DKP-f3-RGD]-PTX 11 is 
sufficiently stable to undergo animal testing with murine models. In fact, similar RGD ligands 
showed significant (maximum) tumor uptakes in mice after 10,29 20,30 30,31 and 60 min.32  
Summarizing, we have investigated the stability of compound 11 to hydrolysis both in a 
physiological solution and in murine and human plasma. As a matter of fact, cyclo[DKP-f3-
RGD]-PTX 11 turned out to be far more stable than PTX-E[cyclo(RGDfK)]2 9
25 (see Figure 3, 
and the relevant discussion in the Introduction). The rather high stability of 11 can possibly be 
attributed to a more lipophilic structure, where the ester linkage is less accessible in the protic 
medium than in Ryppa’s compound 9. 
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Figure 6. Stability of cyclo[DKP-f3-RGD]-PTX 11 in murine and human plasmaa 
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re
a
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aQuantitative HPLC determination of stability of compound 11 (10 µM) in murine plasma (left 
diagram) and in human plasma (right diagram) at 37 °C. 
 
Integrin receptors competitive binding assays. Cyclo[DKP-RGD] - PTX conjugates 10-13 
were examined in vitro for their ability to inhibit biotinylated vitronectin binding to the purified 
αvβ3 and αvβ5 receptors and compared to their unfunctionalized analogs 2, 3, 4 and 6, to the 
unconjugated ligands 64 and 68, and to the reference compounds cyclo[RGDfV]33 and ST1646.34 
The results are collected in Table 1. Screening assays were performed incubating the 
immobilized integrin receptors with various concentrations (10-12 - 10-5 M) of the RGD ligands 
in the presence of biotinylated vitronectin (1 µg/mL), and measuring the concentration of bound 
vitronectin in the presence of the competitive ligands. Low nanomolar values were obtained with 
all the Paclitaxel-RGD constructs (10-13), comparable to the unfunctionalized ligands (2, 3, 4 
and 6). These data reassured us that the enormous increase of steric hindrance in the cyclo[DKP-
RGD] - PTX conjugates, due to presence of the linker bearing Paclitaxel through the succinate 
tether, did not influence the high affinity for integrin receptors αvβ3 and αvβ5. Notably, for 
inhibition of vitronectin binding to the αvβ3 receptor, unconjugated ligand 64 required a 5-fold 
higher concentration than both its unfunctionalized and conjugated analogs (compounds 3 and 
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11, respectively). This reduced affinity may result from perturbation of the electrostatic clamp 
(i.e. the binding interactions of the carboxylate and guanidinium groups with the charged regions 
of the receptor),14 induced by the free amine present in 64.  
 
Table 1. Inhibition of biotinylated vitronectin binding to αvβ3 and αvβ5 receptors 
Compound Structure 
αvβ3  
IC50 [nM]
a 
αvβ5  
IC50 [nM]
a 
10 cyclo[DKP-f2-RGD]-PTXb 8.5 ± 0.8 518 ± 10 
11 cyclo[DKP-f3-RGD]-PTXb 5.2 ± 2.3 219 ± 124 
12 cyclo[DKP-f4-RGD]-PTXb 0.9 ± 0.6 76 ± 32 
13 cyclo[DKP-f6-RGD]-PTXb 1.1 ± 0.1 22 ± 3 
64 cyclo[DKP-f3-RGD]c 26.4 ± 3.7 > 5·103 
68 
cyclo[DKP-f3-RGD]- 
hemisuccinamided 
4.1 ± 0.6 75 ± 1 
2 cyclo[DKP-2-RGD]e 3.2 ± 2.7 114 ± 99 
3 cyclo[DKP-3-RGD]e 4.5 ± 1.1 149 ± 25 
4 cyclo[DKP-4-RGD]e 7.6 ± 4.3 216 ± 5 
6 cyclo[DKP-6-RGD]e 2.1 ± 0.6 79 ± 3 
cyclo[RGDfV]f cyclo[RGDfV] 3.2 ± 1.3 7.5 ± 4.8 
ST1646f ST1646g 1.0 ± 0.5 1.4 ± 0.8 
aIC50 values were calculated as the concentration of compound required for 50% inhibition of 
biotinylated vitronectin binding as estimated by GraphPad Prism software; all values are the 
arithmetic mean ± SD of triplicate determinations. bSee Figure 4. cSee Scheme 4. dCompound 68 
(see Figure 7) was synthesized as described in the Supporting Information. eSee Figure 2. 
fReference compound. gSee Figure 1. 
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Derivatization of the amine with succinic anhydride gave the hemisuccinamide 68 and restored 
the high binding affinity for the αvβ3 receptor. Interestingly, unlike reference compounds 
cyclo(RGDfV) and ST1646, the cyclo[DKP-RGD] peptidomimetics were ca. 20-200 fold more 
selective for the αvβ3 integrin with respect to the αvβ5 in this kind of assay. 
 
Figure 7. Cyclo[DKP-f3-RGD] - hemisuccinamide 
 
 
Sensitivity of tumor cell lines treated with cyclo[DKP-RGD] - PTX conjugates 10-13. 
Cyclo[DKP-RGD] - PTX conjugates 10-13 were tested in vitro for their cytotoxic activity in 
comparison with Paclitaxel, against a panel of human tumor cell lines. The cell sensitivity assays 
(Table 2) clearly indicated that the functionalized cyclo[DKP-f3-RGD] integrin ligand 64 was 
not cytotoxic, while the cyclo[DKP-RGD]-PTX conjugates displayed a cytotoxic activity similar 
to that of Paclitaxel (same order of magnitude). These data imply that free Paclitaxel is released 
at some stage, possibly after the conjugates have been internalized into the cells, because it is 
well known that the free 2’-OH group is necessary for Paclitaxel to exert its cytotoxic and 
microtubule-stabilizing activities.35 Compounds 10-13, 64 and Paclitaxel were also tested in vitro 
on normal HDFC fibroblasts. When cells started to proliferate and were exposed to different 
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concentrations of these compounds (range of concentrations tested = 64-1000 nM), a marginal 
inhibition of cell growth was observed. The effect was not concentration-dependent, suggesting 
that the compounds were not cytotoxic but were at best cytostatic in these cells. The data 
reported in Table 2 did not identify undoubtedly a lead compound for evaluation of antitumor 
activity with in vivo models. Therefore, we chose cyclo[DKP-f3-RGD]-PTX 11 as our lead 
conjugate mainly because of its straightforward synthetic accessibility on a multi-gram scale. 
Flow cytometry was used to detect the expression of αVβ3 and αVβ5 integrins on the surface of 
the different cancer cell lines (Table 3). Among these, the cisplatin-resistant IGROV-1/Pt1 cells 
expressed very high levels of integrin αVβ3, making them attractive to be tested in murine 
models with cyclo[DKP-RGD]-PTX construct 11 (vide infra the in vivo experiments). 
 
Table 2. Cell sensitivity of different tumor cell lines to compounds 10-13 and 64a 
 
Compd Structure 
IC50 (nM) 
IGROV-1 
IGROV-1 
/Pt1 
U2-OS SKOV3 PANC-1 
MIA-
PaCa2 
10 
Cyclo[DKP-f2-
RGD]-PTX 
17.7 ± 6.0 18.7 ± 6.0 2.2 ± 0.5 1.6 ± 1.0 5.8 ± 4.0 2.0 ± 0.7 
11 
Cyclo[DKP-f3-
RGD]-PTX 
61.3 ± 19.1 4.9 ± 2.0 12.8 ± 0.1 1.2 ± 0.1 2.4 ± 0.8 2.3 ± 0.4 
12 
Cyclo[DKP-f4-
RGD]-PTX 
34.4 ± 29.0 3.7 ± 2.0 6.8 ± 4.6 2.4 ± 0.9 3.2 ± 0.7 1.8 ± 0.6 
13 
Cyclo[DKP-f6-
RGD]-PTX 
48.2 ± 2.2 2.4 ± 1.9 5.7 ± 4.4 2.4 ± 1.1 3.5 ± 0.1 2.5 ± 0.6 
64 Cyclo[DKP-f3-RGD] > 1200 > 18000 > 6300 > 11600 > 11600 > 11600 
PTX Paclitaxel 23.0 ± 0.8 2.2 ± 0.8 3.4 ± 0.4 2.7 ± 1.1 5.2 ± 1.9 7.2 ± 3.8 
aCell sensitivity was evaluated by growth inhibition assays based on cell counting. Cells were 
seeded and 24 h later they were exposed to the compounds for 72 h. At the end of treatment, 
cells were counted using a cell counter. 
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 21
Table 3. Integrin expression of tumor cell lines of different tumor typesa 
Integrin 
Mean fluorescence intensity 
IGROV-1 
IGROV-1 
/Pt1 
U2-OS SKOV3 PANC-1 
MIA-
PaCa2 
αVβ3 4.8 ± 1.9 23.3 ± 5.0 1.8 ± 0.6 6.4 ± 0.05 7.9 ± 2.8 1.2 ± 0.1 
αVβ5 3.4 ± 0.9 3.3 ± 0.5 27.4 ±  0.1 4.4 ± 0.5 25.7 ± 6.5 5.6 ± 0.9 
aIntegrin expression levels were examined by immunofluorescence using a flow cytometer. 
The ratios between the mean fluorescence intensity of cells incubated with primary antibody and 
isotypic control are shown. 
 
Comparing the data presented in Tables 2 and 3, it is quite clear that there is no correlation 
between the phenotypic integrin expression levels and efficacy of cyclo[DKP-RGD]-PTX 
conjugates, in in vitro assays. The cell sensitivity studies were carried out to determine whether 
Paclitaxel was released from the conjugate; in these in vitro assays, no tumor homing effect can 
be expected and therefore the different response can be attributed only to a higher or lower 
sensitivity of the different cell lines to the particular compound tested, independently of the 
integrin receptor expression. On the other hand, the evaluation of integrin expression was 
important for the choice of the best in vivo model for efficacy studies (i.e., the choice of 
cisplatin-resistant IGROV-1/Pt1, a cell line where the expression of integrin αvβ3 is particularly 
relevant). 
 
Evaluation of in vivo antitumor activity. Antitumor activity of our lead conjugate 
cyclo[DKP-f3-RGD]-PTX 11, delivered i.v. and administered every 4 days for 4 times (q4dx4), 
was examined on the αVβ3-rich IGROV-1/Pt1 carcinoma grown in athymic mice as 
subcutaneous (s.c.) tumor. A significant, dose-related antitumor effect was observed following 
administration of two dose levels of compound 11 (15 mg/kg and 30 mg/kg). Moreover, when 
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compound 11 (30 mg/kg, i.e. 19.1 µmol/kg) was compared to Paclitaxel (30 mg/kg, i.e. 35.1 
µmol/kg) administered with the same weight dosage and schedule, it displayed better effects in 
terms of tumor volume inhibition (TVI, 85 vs 76%), despite the lower (ca. half) molar dosage 
used (Figure 8). Furthermore, 2 out of 8 tumors in animals receiving conjugate 11 disappeared 
without any evidence of disease until the end of the experiment. Thus, an improved and more 
persistent effect against the growth of treated tumors was achieved, as indicated also by the 
higher Log10 Cell Kill value (LCK, 1.4 vs 0.7, Table 4). Treatment was well tolerated, as no 
deaths or significant weight losses were observed among the treated animals.36 
 
Figure 8. In vivo antitumor activity studies of cyclo[DKP-f3-RGD]-PTX 11 compared to 
Paclitaxel on IGROV-1/Pt1 ovarian carcinomaa 
15 mg/kg 
30 mg/kg 
30 mg/kg 
* 
PTX 
* 
* * 
* 
* 
 
aEfficacy of compound 11 (CPD11) and Paclitaxel (PTX) administered intravenously every 
fourth day for four times on the ovarian carcinoma IGROV-1/Pt1 xenografted subcutaneously in 
athymic nude mice. The solvent was injected for the control group (○). Each point represents the 
mean tumor volume from 8 tumors. Bars represent S.D. *, P < 0.05 by Student’s t test on tumor 
volumes over control mice. 
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Table 4. In vivo antitumor activity and toxicity profile of cyclo[DKP-f3-RGD]-PTX 11 and 
Paclitaxel against human ovarian cancer xenografts (IGROV-1/Pt1) in mice, as a function of 
dose.  
Treatment 
Dose 
(mg/kg) 
Dose 
(µmol/kg) 
TVI%a CRb NEDc LCKd BWL%e D/Tf 
Paclitaxel 30 35.1 76 3/8 0/8 0.7 4 0/4 
Cyclo [DKP-f3-
RGD]-PTX 11 
15 9.6 64 0/8 - 0.3 0 0/4 
Cyclo [DKP-f3-
RGD]-PTX 11 
30 19.1 85 2/8 2/8 1.4 3 0/4 
aTVI%: Tumor Volume Inhibition percent in treated over control mice, calculated 10 d after 
the end of treatments. 
bCR: Complete Response: disappearance of tumors lasting at least 10 days. 
cNED: No Evidence of Disease at the end of experiment (at day 66). 
dLCK: Gross Log10 Cell Kill to reach 600 mm
3 of tumor volume (see Figure 8).  
eBWL%: Body Weight Loss percentage induced by drug treatment.  
fD/T: Dead/Treated mice. 
 
 
Immunohistochemistry analysis of treatment effects. To investigate the mechanism 
underlying the improved antitumor activity of cyclo[DKP-f3-RGD]-PTX 11 over paclitaxel, 
histopathological analysis was carried out in tumors from untreated mice and from mice treated 
with cyclo[DKP-f3-RGD]-PTX 11, compound 64, and Paclitaxel (Figure 9). The comparison 
between Paclitaxel and cyclo[DKP-f3-RGD]-PTX 11 was carried out administering 30 mg/kg for 
both compounds, amounts which correspond to 35.1 µmol/kg for Paclitaxel and to 19.1 µmol/kg 
for cyclo[DKP-f3-RGD]-PTX 11. Histological analysis indicated the presence of a high number 
of mitotic cells in the group treated with cyclo[DKP-f3-RGD]-PTX 11, compared to the other 
groups (Figure 9). In addition, the majority of the mitoses observed in the groups treated with 
Page 23 of 67
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 24
either cyclo[DKP-f3-RGD]-PTX 11 or Paclitaxel were aberrant, an observation consistent with 
the mechanism of action of spindle poisons.37 High levels of aberrant mitoses were observed 
with cyclo[DKP-f3-RGD]-PTX 11, already 24 h after the second treatment and persisted after the 
fourth treatment. On the contrary, the amount of aberrant mitotic cells observed after mice 
treatment with Paclitaxel decreased over time. 
 
Figure 9. Histopathological analysis of IGROV-1/Pt1 xenograft, after treatment with cyclo 
[DKP-f3-RGD]-PTX 11a 
A 
2nd 4th 2nd 4th 
* 
** 
*** 
* 
 
 
B       C 
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D       E 
  
a
A. Quantitative analysis of mitoses. Mitoses were evaluated in 3 randomly selected 400x 
fields using quadruplicate samples. The reported numbers correspond to the mean number of 
normal/aberrant mitoses in analyzed groups: control groups (control); groups treated with 
compound 64 (CPD64); group treated with compound 11 (CPD11); groups treated with 
Paclitaxel (PTX). Note that tumors were obtained from mice sacrificed 24 h after the second or 
the fourth treatment. B. Randomly selected high power field (hpf) within the bulk of the tumor 
from a control group sample, characterized by normal mitoses (hematoxyilin and eosin; Bar, 50 
µm). C. Randomly selected hpf within the bulk of the tumor from a sample treated with 
compound 64. Hyperchromatic nuclei with condensed chromatin are evident (hematoxylin and 
eosin; Bar, 50µm). D. Randomly selected hpf within the bulk of the tumor from a sample treated 
with compound 11. Note markedly aberrant mitoses, with formation of nuclear envelops around 
individual clusters of missegregated chromosomes (mitotic catastrophe) (hematoxylin and eosin; 
Bar, 50µm). E. Randomly selected hpf within the bulk of the tumor from a sample treated with 
Paclitaxel. Note markedly aberrant mitoses, with formation of nuclear envelops around 
individual clusters of missegregated chromosomes (mitotic catastrophe) (hematoxylin and eosin; 
Bar, 50µm). 
 
Since tumors from mice treated with cyclo[DKP-f3-RGD]-PTX 11 had the highest number of 
mitoses and the major part of them were atypical, it is likely that tumor cells treated with 
compound 11 entered mitosis, but failed to replicate and incurred in mitotic arrest.  
 
CONCLUSIONS 
In conclusion, since αV integrins are overexpressed on the surface of cancer cells, we have 
synthesized a small library of integrin ligand - Paclitaxel conjugates 10-13 with the aim of using 
the tumor-homing cyclo[DKP-RGD] peptidomimetics for site-directed delivery of the cytotoxic 
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drug. All the Paclitaxel-RGD constructs 10-13 inhibited biotinylated vitronectin binding to the 
purified αVβ3 receptor at low nanomolar concentration, showing that the enormous increase of 
steric hindrance in the conjugates, due to presence of the linker bearing Paclitaxel through the 
succinate tether, did not influence the high affinity for the integrin receptors. Cyclo[DKP-RGD]-
PTX conjugates 10-13 showed in vitro cytotoxic activity against a panel of human tumor cell 
lines similar to that of Paclitaxel. Among the cell lines, the cisplatin-resistant IGROV-1/Pt1 cells 
expressed high levels of integrin αVβ3, making them attractive to be tested in in vivo models. 
Cyclo[DKP-f3-RGD]-PTX 11 displayed sufficient stability in physiological solution and in both 
human and murine plasma to be a good candidate for in vivo testing. In tumor-targeting 
experiments against the IGROV-1/Pt1 human ovarian carcinoma xenotransplanted in nude mice, 
compound 11 exhibited better effects than Paclitaxel in terms of tumor volume inhibition and 
Log10 Cell Kill, despite the lower (ca. half) molar dosage used. Moreover, 2 out of 8 tumors in 
animals receiving conjugate 11 disappeared without any evidence of disease until the end of 
experiment, suggesting an improved and more persistent antitumor effect. Treatment was well 
tolerated, as no deaths or significant weight losses were observed among the treated animals. 
Comparison of the in vitro data shown in Table 2 (where conjugate 11 is apparently two-fold less 
cytotoxic than Paclitaxel with respect to the IGROV-1/Pt-1 cancer cell line) with the in vivo data 
of Table 4 and Figure 8 (where conjugate 11 shows a superior antitumor effect compared to 
Paclitaxel against the IGROV-1/Pt1 human ovarian carcinoma xenotransplanted in nude mice) is 
not contradictory but rather reinforces the tumor homing effect claimed for compound 11. In 
fact, in vivo the conjugate is targeted to the tumor, whereas in vitro it acts through release of 
Paclitaxel. The histological examination of tumor specimens supports this view, because the 
induction of aberrant mitosis observed after treatment with conjugate 11 was more frequent, 
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pronounced and persistent than that observed with Paclitaxel (see Figure 9A, right diagram), 
consistent with a successful drug delivery to the target. The superior in vivo activity of 
cyclo[DKP-f3-RGD]-PTX 11 as compared to Paclitaxel supports the view that integrin ligands 
are promising tools to improve delivery of cytotoxic drugs.  
 
EXPERIMENTAL SECTION 
 
MATERIALS AND METHODS. All manipulations requiring anhydrous conditions were 
carried out in flame-dried glassware, with magnetic stirring and under a nitrogen atmosphere. All 
commercially available reagents were used as received. Anhydrous solvents were purchased 
from commercial sources and withdrawn from the container by syringe, under a slight positive 
pressure of nitrogen. (S)- and (R)-serine methyl ester hydrochloride,38 (2R)- and (2S)-aspartic 
acid β-allyl ester hydrochloride,39 N-(tert-butoxycarbonyl)-(2R)-aspartic acid β-allyl ester,39 (S)- 
and (R)-N-Boc-serine methyl ester,40 (S)- and (R)-methyl 3-azido-2-(tert-
butoxycarbonylamino)propanoate,41 (S)- and (R)-3-azido-2-(tert-butoxycarbonylamino) 
propanoic acid,41 (S)- and (R)-dimethyl aspartate hydrochloride,42 (S)- and (R)-N-benzyl-
dimethyl aspartate43 and N-Boc-glycine benzyl ester44 were prepared according to literature 
procedures and their analytical data were in agreement with those already published. Reactions 
were monitored by analytical thin layer chromatography using 0.25 mm pre-coated silica gel 
glass plates (DURASIL-25 UV254) and compounds visualized using UV fluorescence, aqueous 
potassium permanganate or ninhydrin. Flash column chromatography was performed according 
to the method of Still and co-workers45 using Chromagel 60 ACC (40-63 µm) silica gel. Melting 
points were obtained in an open capillary apparatus and are uncorrected. 1H-NMR spectra were 
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recorded on a spectrometer operating at 400.16 MHz. Proton chemical shifts are reported in ppm 
(δ) with the solvent reference relative to tetramethylsilane (TMS) employed as the internal 
standard. The following abbreviations are used to describe spin multiplicity: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad signal, dd = doublet of doublet. 
13C-NMR spectra were recorded on a spectrometer operating at 100.63 MHz, with complete 
proton decoupling. Carbon chemical shifts are reported in ppm (δ) relative to TMS with the 
respective solvent resonance as the internal standard. Infrared spectra were recorded on a 
standard FT-IR and peaks are reported in cm–1. Optical rotation values were measured on an 
automatic polarimeter with a 1 dm cell at the sodium D line and are given in units of 10-1 deg 
cm2 g-1. High resolution mass spectra (HRMS) were performed on a Fourier Transform Ion 
Cyclotron  Resonance (FT-ICR) Mass Spectrometer APEX II & Xmass software (Bruker 
Daltonics) – 4.7 T Magnet (Magnex) equipped with ESI source, available at CIGA (Centro 
Interdipartimentale Grandi Apparecchiature) c/o Università degli Studi di Milano. Low 
resolution mass spectra (MS) were measured on a Waters Acquity UPLC-MS (ESI ion source). 
All described compounds showed a purity > 98%, as determined by HPLC (UV and MS 
detectors). LC-UV/MS data were collected with an Agilent 1100 HPLC connected to a Bruker 
Esquire 3000+ ion trap mass spectrometer through an ES interface. 
Cancer cell lines IGROV-1 e IGROV-1/Pt1 were obtained as previously reported.46 Cancer 
cell lines U2OS, SKOV3, PANC-1 and MIA Paca2 are ATCC cultures, registered as follows. 
U2OS: ATCC HTB-96. SKOV3: ATCC HTB-77. PANC-1: ATCC CRL-1469. MIA PaCa2: 
ATCC CRL-1420. 
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SOLID-PHASE RECEPTOR-BINDING ASSAY. Purified αvβ3 and αvβ5 receptors 
(Chemicon International, Inc., Temecula, CA, USA) were diluted to 0.5 µg/mL in coating buffer 
containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM MnCl2, 2 mM CaCl2 and 1 mM 
MgCl2. An aliquot of diluted receptors (100 µL/well) was added to 96-well microtiter plates 
(NUNC MW 96F MEDISORP STRAIGHT) and incubated overnight at 4 °C. The plates were 
then incubated with blocking solution (coating buffer plus 1% bovine serum albumin) for 
additional 2 hours at room temperature to block nonspecific binding followed by 3-hour 
incubation at room temperature with various concentrations (10-12–10-5 M) of test compounds in 
the presence of 1 µg/mL biotinylated vitronectine. Biotinylation was performed using EZ-Link 
Sulfo-NHS-Biotinylation kit (Pierce, Rockford, IL). After washing, the plates were incubated for 
1 hour at room temperature with streptavidin-biotinylated peroxidase complex (Amersham 
Biosciences, Uppsala, Sweden) followed by 30 minutes incubation with 100 µL Substrate 
Reagent Solution (R&D Systems, Minneapolis, MN) before stopping the reaction by addition of 
50 µL of 2 N H2SO4. Absorbance at 415 nm was read in a Synergy™ HT Multi-Detection 
Microplate Reader (BioTek Instruments, Inc.). Each data point is the result of the average of 
triplicate wells and was analyzed by nonlinear regression analysis with Prism GraphPad 
program. 
 
GENERAL PROCEDURE A FOR DEPROTECTION REACTIONS. To a solution of the 
N-Boc-protected  amino acid or peptide in CH2Cl2 (0.13 M) was added half volume of TFA and 
the reaction was stirred at rt for 2 h. The solvent was evaporated, toluene (2×) was added 
followed by evaporation, and then ether was added and evaporated to afford the corresponding 
TFA salt.  
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GENERAL PROCEDURE B FOR COUPLING REACTIONS. To a solution of the N-
protected amino acid in DMF, under nitrogen atmosphere and at 0 ºC, HATU (1.2 equiv), HOAt 
(1.2 equiv) and i-Pr2NEt (4 equiv) were added. After 30 min, a solution of the TFA salt of the 
peptide in DMF was added and the reaction mixture was stirred at 0 ºC for 1 h and at rt 
overnight. The mixture was diluted with AcOEt and consecutively washed with 1 M KHSO4 
(2×), aqueous NaHCO3 (2×) and brine (2×), dried over Na2SO4 and the solvent evaporated under 
reduced pressure to afford the crude product. 
 
GENERAL PROCEDURE C FOR THE SYNTHESIS OF cyclo[DKP-RGD] 
PACLITAXEL CONJUGATES 10-13. Diisopropylcarbodiimide (11.93 µL, 9.72 mg, 0.077 
mmol, 1.9 equiv) was added to a solution of 2’-succinyl-Paclitaxel 67 (49 mg, 0.0513 mmol, 
1.25 equiv) and N-hydroxysulfosuccinimide sodium salt (13.94 mg, 0.0642 mmol, 1.55 equiv) in 
dry dimethylformamide (2.0 mL). The resulting solution was stirred under argon at room 
temperature for 24 h. Volatiles were then removed in vacuo to give an off-white solid, which was 
re-dissolved in acetonitrile (2 mL). A solution of the appropriate cyclo[DKP-RGD] (63-66) (35 
mg, 0.0414 mmol) in pH 7.0 phosphate buffer (0.5 M, 1.0 mL) was then added to the acetonitrile 
solution, and the pH was adjusted to 7.3 with NaOH (0.2 M, a few drops). The resulting solution 
was rapidly cooled to 0 °C and stirred for 10 hours, warmed to room temperature and stirred for 
further 18 h. During the entire period the pH value was kept near 7.3 adding 0.1 M aqueous 
NaOH, when required. Dioxane/water (1:1, 10 mL) was then added to the reaction mixture and 
the resulting solution was freeze-dried. The solid recovered from freeze-drying was purified by 
semipreparative-HPLC [Water's Atlantis 21 mm x 10 cm column, gradient: 90% (H2O + 0.1% 
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HCOOH) / 10% (CH3CN + 0.1% HCOOH) to 30% (H2O + 0.1% HCOOH) / 70% (CH3CN + 
0.1% HCOOH)]. The purified products were then freeze dried to give the desired compounds 
(10-13) as white solids. 
 
Cyclo[DKP-f2-RGD]-PTX 10. Compound 10 was synthesized according to general procedure 
C (40 mg, 60% yield). 1H NMR (400 MHz, CD3OD) δ 8.09 (dd, 2H, J = 8.4, 1.2 Hz), 7.84 (dd, 
2H, J = 7.1, 1.6 Hz), 7.74 (tt, 1H, J = 6.8, 1.6 Hz), 7.64 (t, 2H, J = 7.6 Hz), 7.59-7.54 (m, 1H), 
7.49-7.44 (m, 6H), 7.28-7.25 (m, 4H), 7.22 (tt, 1H, J = 5.8, 2.8 Hz), 6.43 (s, 1H), 5.98 (t, 1H, J = 
9.1 Hz), 5.69 (d, 1H, J = 7.9 Hz), 5.61 (d, 1H, J = 7.0 Hz), 5.45 (d, 1H, J = 7.9 Hz), 5.24 (d, 1H, 
J = 15.1 Hz), 5.10 (dd, 1H, J = 9.7, 1.6 Hz), 4.77 (m overlapped with water signal, 1H), 4.65 (m 
overlapped with water signal, 1H), 4.40-4.30 (m, 4H), 4.21 (m, 3H), 4.08 (d, 2H, J = 15.7 Hz), 
3.85 (d, 1H, J = 4.6 Hz), 3.78 (d, 1H, J = 7.0 Hz), 3.64 (d, 1H, J = 16.3 Hz), 3.28 (m overlapped 
with solvent signal, 1H), 3.22 (t, 2H, J = 6.7 Hz), 2.98 (dd, 1H, J = 13.2, 7.4 Hz), 2.84-2.75 (m, 
2H), 2.71-2.68 (m, 2H), 2.64-2.50 (m, 3H), 2.37-2.34 (m, 4H), 2.18 (s, 3H), 2.01 (m, 1H), 1.89-
1.79 (m, 5H), 1.75-1.59 (m, 7H), 1.14 (s, 3H), 1.11 (s, 3H); 13C NMR (101 MHz, CD3OD) δ 
205.7, 175.8, 175.0, 174.5, 174.17, 174.02, 173.7, 172.09, 171.96, 171.1, 170.74, 170.54, 169.8, 
168.0, 158.3, 142.3, 139.6, 137.9, 135.5, 135.04, 134.95, 134.7, 133.2, 131.1, 130.8, 130.2, 
129.94, 129.82, 129.71, 129.3, 129.0, 128.64, 128.46, 85.9, 82.0, 79.1, 77.5, 76.7, 76.14, 76.06, 
72.9, 72.1, 60.3, 59.1, 55.8, 55.4, 53.2, 51.3, 48.1, 47.8, 44.3, 43.7, 43.0, 40.7, 39.9, 37.32, 37.21, 
36.0, 31.0, 29.9, 28.2, 26.8, 26.2, 23.4, 22.3, 20.9, 15.0, 10.6; IR (film) 3361, 3075, 2940, 1730, 
1715, 1698, 1667, 1538, 1422, 1243, 1135, 1072 cm-1; MS (ESI) m/z calcd. for [C78H92N11O24]
+: 
1566.63 [M+H]+; found: 1566.6. 
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Cyclo[DKP-f3-RGD]-PTX 11. Compound 11 was synthesized according to general procedure 
C (47 mg, 70% yield). 1H NMR (400 MHz, CD3OD) δ 8.12 (dd, 2H, J = 8.5, 1.4 Hz), 7.83 (dd, 
2H, J = 8.5, 1.4 Hz), 7.71-7.66 (m, 1H), 7.60 (t, 2H, J = 7.5 Hz), 7.56-7.52 (m, 1H), 7.50-7.42 
(m, 6H), 7.30 (s, 4H), 7.25 (tt, 1H, J = 7.1, 1.6 Hz), 6.45 (s, 1H), 6.05 (td, 1H, J = 9.1, 1.0 Hz), 
5.79 (d, 1H, J = 6.5 Hz), 5.64 (d, 1H, J = 7.2 Hz), 5.44 (d, 1H, J = 6.5 Hz), 5.13 (d, 1H, J = 14.9 
Hz), 5.03 (dd, 1H, J = 9.4, 1.6 Hz), 4.91-3.86 (m, 1H), 4.75 (dd, 1H, J = 6.5, 4.7 Hz), 4.44-4.36 
(m, 3H), 4.30-4.22 (m, 2H), 4.20 (br s, 2H, J = 4.2 Hz), 4.16 (ddd, 1H, J = 12.0, 8.7, 3.6 Hz), 
4.09-4.08 (m, 2H), 3.90 (d, 1H, J = 6.0 Hz), 3.82 (d, 1H, J = 7.1 Hz), 3.74-3.68 (m, 2H), 3.61 (d, 
1H, J = 17.2 Hz), 3.54 (dt, 1H, J = 11.7, 2.8 Hz), 3.42 (dd, 1H, J = 14.6, 6.4), 3.27-3.16 (m, 2H), 
2.80-2.75 (m, 2H), 2.72-2.51 (m, 7H), 2.37 (s, 3H), 2.18-2.12 (m, 4H), 2.09-2.01 (m, 1H), 1.92 
(s, 3H), 1.86-1.76 (m, 3H), 1.68-1.63 (m, 5H), 1.14 (s, 3H), 1.13 (s, 3H); 13C NMR (101 MHz, 
CD3OD) δ 205.5, 174.0, 173.60, 173.46, 173.0, 171.63, 171.54, 171.46, 171.2, 170.5, 167.7, 
142.4, 140.2, 138.4, 135.5, 134.80, 134.63, 132.9, 131.39, 131.22, 130.1, 129.72, 129.60, 129.56, 
129.3, 128.6, 100.0, 85.9, 82.3, 79.0, 77.5, 76.9, 76.2, 75.9, 72.9, 72.4, 61.6, 60.6, 59.2, 55.4, 
54.4, 53.2, 50.5, 48.0, 44.6, 43.76, 43.69, 42.2, 39.9, 37.6, 36.49, 36.36, 31.1, 29.8, 27.7, 26.9, 
26.5, 25.1, 23.3, 22.3, 20.8, 15.1, 10.5; IR (film) 3360, 3075, 2940, 1729, 1714, 1693, 1665, 
1537, 1421, 1241, 1135, 1071 cm-1; MS (ESI) m/z calcd. for [C78H92N11O24]
+: 1566.63 [M+H]+; 
found: 1566.6. 
 
Cyclo[DKP-f4-RGD]-PTX 12. Compound 12 was synthesized according to general procedure 
C (42 mg, 63% yield). 1H NMR (400 MHz, DMSO-d6) δ 9.22 (d, 1H, J = 8.5 Hz), 8.95 (s, 1H), 
8.79 (s, 1H), 8.44-8.40 (m, 1H), 8.35 (t, 1H, J = 5.7 Hz), 8.20 (s, 1H), 7.98 (dd, 2H, J = 7.1, 1.3 
Hz), 7.86 (dd, 2H, J = 7.2, 1.3 Hz), 7.76-7.69 (m, 1H, J = 1.5 Hz), 7.69-7.63 (m, 2H), 7.59-7.53 
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(m, 1H), 7.49 (d, 1H, J = 7.6 Hz), 7.46-7.42 (m, 5H), 7.23-7.17 (m, 5H), 6.30 (s, 1H), 5.83 (t, 
1H, J = 8.9 Hz), 5.54 (t, 1H, J = 8.7 Hz), 5.42 (d, 1H, J = 7.1 Hz), 5.36 (d, 1H, J = 8.9 Hz), 5.21 
(d, 1H, J = 14.4 Hz), 4.92 (d, 2H, J = 10.6 Hz), 4.62 (s, 1H), 4.27-4.07 (m, 5H), 4.04-3.99 (m, 
3H), 3.94-3.87 (m, 1H), 3.83-3.79 (m, 1H), 3.70 (br s, 2H), 3.58 (d, 1H, J = 7.1 Hz), 3.43-3.26 
(m overlapped with water signal, 2H), 3.07 (br s, 2H), 2.89 (br s, 2H), 2.69-2.56 (m, 3H), 2.45 (t, 
2H, J = 6.8 Hz), 2.38-2.30 (m, 2H), 2.24-2.20 (m, 4H), 2.10 (s, 3H), 1.84-1.76 (m, 5H), 1.64 (t, 
1H, J = 12.4 Hz), 1.54-1.41 (m, 7H), 1.02 (s, 3H), 1.00 (s, 3H); 13C NMR (101 MHz, DMSO-d6) 
δ 202.3, 173.9, 172.13, 171.94, 170.8, 170.2, 169.63, 169.50, 169.1, 168.84, 168.74, 168.3, 
167.9, 166.4, 165.2, 157.3, 139.4, 138.7, 137.3, 134.8, 134.3, 133.45, 133.33, 132.7, 131.4, 
129.95, 129.93, 129.56, 129.54, 128.73, 128.65, 128.55, 128.29, 128.14, 127.83, 127.71, 127.65, 
127.4, 83.6, 80.2, 76.7, 75.3, 74.68, 74.54, 74.50, 72.5, 70.7, 70.4, 57.4, 56.1, 53.98, 53.86, 
52.17, 52.13, 46.1, 44.9, 42.9, 42.1, 41.9, 40.1, 39.9, 38.2, 36.5, 35.7, 34.4, 29.5, 28.7, 27.6, 26.3, 
25.3, 22.5, 21.4, 20.63, 20.52, 13.9, 9.7; IR (film) 3370, 3071, 2941, 1731, 1714, 1699, 1667, 
1538, 1421, 1243, 1135, 1071 cm-1; MS (ESI) m/z calcd. for [C78H92N11O24]
+: 1566.63 [M+H]+; 
found: 1566.6 
 
Cyclo[DKP-f6-RGD]-PTX 13. Compound 13 was synthesized according to general procedure 
C (43 mg, 65% yield). 1H NMR (400 MHz, DMSO-d6) δ 9.42 (s, 1H), 9.25 (d, 1H, J = 8.5 Hz), 
8.74 (s, 1H), 8.62 (s, 1H), 8.45 (s, 1H), 8.37 (t, 1H, J = 5.7 Hz), 7.99-7.97 (m, 2H), 7.87-7.84 (m, 
3H), 7.73 (t, 1H, J = 7.3 Hz), 7.66 (t, 2H, J = 7.4 Hz), 7.56 (tt, 1H, J = 7.3, 2.0 Hz), 7.50-7.44 
(m, 7H), 7.25-7.15 (m, 5H), 6.30 (s, 1H), 5.83 (t, 1H, J = 8.8 Hz), 5.53 (t, 1H, J = 8.7 Hz), 5.41 
(d, 1H, J = 7.2 Hz), 5.35 (d, 1H, J = 9.0 Hz), 5.11 (d, 1H, J = 14.9 Hz), 4.98-4.90 (t, 2H), 4.64 (s, 
1H), 4.29-4.20 (m, 3H), 4.17-4.08 (m, 2H), 4.04-3.95 (m, 3H), 3.93-3.79 (m, 3H), 3.74-3.64 (m, 
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1H), 3.59 (d, 1H, J = 6.8 Hz), 3.53-3.43 (m, 1H), 3.26-3.19 (m, 1H), 3.07 (br s, 1H), 2.97 (br s, 
1H), 2.72-2.58 (m, 4H), 2.56-2.52 (m, 1H), 2.45 (t, 2H, J = 6.8 Hz), 2.40-2.28 (m, 2H), 2.23 (s, 
3H), 2.10 (s, 3H), 1.82-1.60 (m, 7H), 1.52-1.46 (m, 6H), 1.02 (s, 3H), 1.00 (s, 3H); 13C NMR 
(101 MHz, DMSO-d6) δ 202.7, 172.0, 171.8, 170.3, 169.72, 169.57, 169.2, 168.79, 168.72, 
166.8, 166.4, 165.2, 157.3, 139.5, 137.4, 135.2, 134.3, 133.5, 133.32, 133.28, 132.7, 131.5, 
129.9, 129.6, 128.7, 128.38, 128.21, 128.0, 127.7, 127.5, 83.6, 80.3, 76.7, 75.3, 74.69, 74.62, 
74.49, 70.7, 70.4, 57.2, 54.4, 54.1, 51.98, 51.92, 46.10, 45.97, 43.0, 41.9, 40.9, 39.7, 37.8, 36.6, 
34.4, 29.5, 28.7, 28.0, 26.4, 24.4, 22.6, 21.4, 20.7, 14.0, 9.8; IR (film) 3365, 3071, 2940, 1732, 
1716, 1699, 1665, 1537, 1421, 1243, 1135, 1071 cm-1; MS (ESI) m/z calcd. for [C78H92N11O24]
+: 
1566.63 [M+H]+; found: 1566.6. 
 
 
PLASMA STABILITY ASSAYS. A 10 mM stock solution of cyclo[DKP-f3-RGD]-PTX 11 
(MW 1566.62) was obtained by dissolving 2 mg of compound in 127.66 µL of DMSO. A further 
dilution 1:50 in pH 7.5 phosphate buffer (PBS) was performed (10 µL of stock solution into 490 
µL PBS) to obtain a 200 µM solution; from this last solution, 25 µL were spiked into 475 µL of 
plasma (murine or human) to obtain the final concentration of 10 µM. Standards (lidocaine and 
2-Piperidinoethyl-4-amino-5-chloro-2-methoxybenzoate) were tested at 2.5 µM final 
concentration starting from a 500 µM stock solution in DMSO, further diluted 1:10 into PBS and 
1:20 into plasma. 
Aliquots of 50 µL volume were taken at 0, 15, 30, 60, 120, 180 and 300 minutes of incubation 
at 37 °C and immediately quenched with 200 µL of a solution of Verapamil 250 ng/mL (internal 
standard) in acetonitrile. Samples were centrifuged for 20 min at 3000 rpm and supernatants 
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analyzed by UPLC (Waters) interfaced with a Premiere XE Triple Quadrupole (Waters). Eluents 
were Phase A: 95% H2O, 5% CH3CN + 0.1% HCOOH and Phase B: 5% H2O, 95% CH3CN + 
0.1% HCOOH. Waters UPLC: flow 0.6 mL/min, column BEH C18, 50x2.1 mm 1.7 µm at 50 °C, 
vol inj. 5 µL. Samples were analyzed in multiple reaction monitoring (MRM) conditions: ESI 
Positive, Desolvation Temperature 450 °C, Desolvation Gas 900 L/h, Cone Gas 90 L/h, Collision 
Gas 0.2 L/h. Results are presented as Mean ± S.D., n=2 for standards, n=3 for cyclo[DKP-f3-
RGD]-PTX 11. 
 
CELL SENSITIVITY STUDIES. The human ovarian carcinoma IGROV-1 cell line,46 the 
cisplatin-resistant IGROV-1/Pt1 subline46 the human ovarian carcinoma cell line SKOV3, the 
human pancreatic carcinoma cell lines PANC-1 and MIA-PaCa2 were cultured in Dulbecco's 
Modified Eagle Medium (DMEM) medium; the human osteosarcoma U2-OS cell line was grown 
in Mc Coy’s 5A medium; HDFC cells were cultured in DMEM-F12 medium. In all cases, the 
medium was supplemented with 10% fetal calf serum. The cell sensitivity to drugs was measured 
by using the growth-inhibition assay based on cell counting. Cells were seeded in duplicates into 
6-well plates and exposed to drug 24 h later. Paclitaxel and the studied compounds were 
dissolved in DMSO and then added to culture medium. DMSO concentration in medium never 
exceeded 0.25%. After 72 h of drug incubation, cells were harvested for counting with a cell 
counter (Z1 Beckman Coulter counter). IC50 is defined as the drug concentration producing 50% 
decrease of cell growth. At least five independent experiments were performed. 
 
ANALYSIS OF INTEGRIN LEVELS. The expression of integrins was measured by flow 
cytometry, following optimization of antibody concentration. Exponentially growing cells were 
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harvested and incubated fro 30 min at 4 °C with anti human αvβ3 or αvβ5 antibodies or isotypic 
controls (Millipore, Temecula, CA; Chemicon International). Cells were than washed and 
samples were immediately used for flow cytometric analysis (FACScan, Becton-Dickinson). 
Expression of integrins was expressed as ratio between the mean fluorescence intensity obtained 
in cells incubated with anti-integrin antibodies divided by that of cells incubated with isotypic 
control. 
 
IN VIVO ANTITUMOR ACTIVITY STUDIES.  All experiments of were carried out using 
female athymic Swiss nude mice, 8-10 weeks-old (Charles River, Calco, Italy). Mice were 
maintained in laminar flow rooms keeping temperature and humidity constant. Mice had free 
access to food and water. Experiments were approved by the Ethics Committee for Animal 
Experimentation of the Istituto Nazionale Tumori of Milan according to institutional guidelines. 
The IGROV-1/Pt1 human tumor xenograft, derived from cultures of the corresponding ovarian 
carcinoma cell line,46 was used. Exponentially growing cells (107/mouse) were s.c. injected into 
the right flank of athymic nude mice and the tumor line was achieved by serial s.c. passages of 
fragments of re-growing tumors into healthy mice. Groups of four mice bearing bilateral s.c. 
tumors were employed. Tumor fragments were implanted on day 0 and tumor growth was 
followed by biweekly measurements of tumor diameters with a Vernier caliper. Tumor volume 
(TV) was calculated according to the formula: TV (mm3) = d2xD/2 where d and D are the 
shortest and the longest diameter, respectively. Compounds were delivered i.v. and administered 
every 4 days for 4 times (q4dx4). Treatment started three days after tumor implant, when tumors 
were just palpable. The efficacy of the drug treatment was assessed as: 1) Tumor volume 
inhibition percentage (TVI%) in treated versus control mice, calculated as: TVI% = 100-(mean 
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TV treated/mean TV control x 100);  2) Log10 cell kill (LCK) calculated by the formula: LCK = 
(T-C)/3.32xDT where T and C are the mean times (days) required for treated (T) and control (C) 
tumors, respectively, to reach an established TV and DT is the doubling time of control tumors, 
obtained from semilog best-fit curves of mean tumor volumes plotted against time; 3) Complete 
regression (CR), i.e. disappearance of the tumor lasting at least 10 days after the end of 
treatments. Tumors not regrown at the end of experiment were considered no evidence of disease 
(NED). The toxicity of the drug treatment was determined as body weight loss (BWL) and lethal 
toxicity (D/T, dead/treated mice). The highest body weight loss percentage induced by 
treatments is reported in the Tables. Deaths occurring in treated mice before the death of the first 
control mouse were ascribed to toxic effects. Two-sided Student’s t test was used for statistical 
comparison of tumor volumes in control over treated mice. For in vivo studies, Paclitaxel was 
dissolved in a mixture of ethanol and cremophor ELP (50+50%) and kept at 4 °C. At treatment 
the drug was diluted in 90% of cold saline after magnetic stirring and administered i.v.. 
Cyclo[DKP-f3-RGD]-PTX 11 was dissolved and administered like Paclitaxel at room 
temperature. 
 
IMMUNOHISTOCHEMISTRY. Tumor xenografts and adjacent tissues were excised and 
formalin fixed and paraffin embedded. Four µm sections from each tumor xenograft were 
routinely stained with Hematoxylin-Eosin (HE) and evaluated under a light microscope. Mitoses 
were evaluated in 3 randomly selected 400x fields within the bulk of the xenograft, avoiding 
areas of necrosis and hemorrhage. The total number of mitoses and the mean value for each 
sample were evaluated. Furthermore, mitoses were classified as “normal” and “aberrant”, 
considering in this latter class both small condensed hyperchromatic nuclei and large cells 
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composed by nuclear envelope around individual clusters of missegregated chromosomes 
(mitotic catastrophe), and the ratio between these two classes was evaluated. The analysis of 
mitoses was performed in a blind fashion. Statistical analysis of the obtained data was carried out 
with Kruskal Wallis test followed by Dunn’s multiple comparison test using GraphPad Prism 
(GraphPad Software, Inc.). 
 
ASSOCIATED CONTENT 
Supporting Information 
General information for the synthesis, biological procedures, detailed experimental procedures 
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ABBREVIATIONS USED 
DKP, diketopiperazine; Mtr, 4-methoxy-2,3,6-trimethylbenzenesulphonamide; HATU, O-(7-
azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate; Tol, toluene; TEA, 
triethylamine; HOAT, 1-hydroxy-7-azabenzotriazole; DIAD, diisopropyl azodicarboxylate; 
BOC-ON, 2-(Boc-oxyimino)-2-phenylacetonitrile; DCU, N,N′-dicyclohexylurea; PyBrOP, 
bromotripyrrolidinophosphonium hexafluorophosphate; DPPA, diphenyl phosphoryl azide; EDT, 
1,2-ethanedithiol; TIPS, triisopropylsilane; DIC, N,N′-diisopropylcarbodiimide; sulfo-NHS, N-
hydroxysulfosuccinimide sodium salt; PTX, Paclitaxel; RP-HPLC, reverse phase high-pressure 
liquid chromatography; HDFC, human dermal fibroblast cells; TVI, tumor volume inhibition; 
CR, complete response; NED, no evidence of disease; LCK, log10 cell kill; BWL, body weight 
loss; D/T, dead/treated mice; CPD, compound; MRM, multiple reaction monitoring; DMEM, 
Dulbecco's modified eagle medium; TV, tumor volume. 
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